

REMARKS/ARGUMENTS

Claims 42-55 and 62-64 are pending.

Applicants would like to thank Examiner Ford for indicating that Claims 42-52 are allowed, and for helpful comments regarding claim amendments.

The rejection of Claims 53-55 under 35 U.S.C. §112, second paragraph, is believed to be obviated by the amendment submitted above. Those claims have been amended to recite an adjuvant. Accordingly, withdrawal of this ground of rejection is respectfully requested.

The various rejections of Claims 56-61 are moot in view of the cancellation of those claims. Newly-added Claims 62-64 are directed to a method of antagonizing N-type calcium channels, comprising contacting N-type calcium channels with an effective amount of the inventive compounds. Applicants submit that those claims are allowable. See, especially page 4 of the present specification. Withdrawal of the rejections applied against Claims 56-61 is respectfully requested.


Applicants submit that the present application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/03)



James J. Kelly, Ph.D.
Registration No. 41,504